The quality-of-life questionnaire QLS-H©: Validation of the French language version of the questionnaire in patients with growth hormone deficiency and collection of reference data in the general population;Le questionnaire de qualité de vie QLS-H©: Validation de la version Française chez les patients avec déficit en hormone de croissance et acquisition des valeurs de référence dans la population générale

Annales d'Endocrinologie

Volumn 65, Issue 5, 2004, Pages 439-450

  Rosilio, M ^a   Berthezene F ^b   Blum, W F ^c   Shavrikova, E P ^d   Herschbach, P ^e   Henrich, G ^e  

^a Lilly France   (France)

^b HÔPITAL NEUROLOGIQUE   (France)

^c ELI LILLY AND COMPANY   (United States)

^d Pharma Support Inc   (Russian Federation)

^e Medizin Psychotherap Med Psychol   (Germany)

Author keywords

Adult growth hormone deficiency; Qls h ; Quality of life

Indexed keywords

GROWTH HORMONE;

ADULT; AGED; ALGORITHM; ARTICLE; FEMALE; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOPITUITARISM; LIFE SATISFACTION; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; QUALITY OF LIFE SATISFACTION HYPOPITUITARISM; QUESTIONNAIRE; SAMPLING; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 9344229830     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0003-4266(04)95949-5     Document Type: Article

References (29)

1. Attanasio AF, Lamberts QWJ, Matranga AMC et al. Adult growth hormone (GH) deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. J Clin Endocrinol Metab 1997; 82: 82-8.
2. Bengtsson BA, Abs R, Bennmarker H et al. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH deficient adults. IMS study group and the KIMS international Board. J Clin Endocrinol Metab 1999; 84: 3929-35.
3. Slum WF, Shavzikova EP, Edwards DJ et al. Decreased quality of life in adult patients with growth hormone deficiency compared with general populations using the new, validated, self-weighted questionnaire QLS-H. J Clin Endocrinol Metab 2003; 88: 4158-67.
4. Bucquet D, Condom S, Ritchie K. The French version of the Nottingham Health Profile. A comparison of item weights with those of the source version. Social Sci Med 1990; 30: 829-35.
5. Bülow B, Hagmar L, Orbaek P, Osterberg K, Erfurth EM. High incidence of mental disorders, reduced mental well-being and cognitive function in hypopituitary women with GH deficiency treated for pituitary disease. Clin Endocrinol (Oxf) 2002; 56: 183-93.
6. Burman P, Broman JE, Hetta J et al. Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo controlled 21-month trial. J Endocrinol Metab 1995; 80: 3585-90.
7. Chipman JJ, Attanasio AF, Birkett MA, Bates PC, Webb S, Lamberts SW. The safety profile of GH replacement therapy in adults. Clin Endocrinol (Oxf) 1997; 46: 473-81.
8. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society workshop on adult growth hormone deficiency. J Clin Endocrinol Metab 1998; 83: 379-81.
9. Cummings DE, Merriam GR. Growth hormone therapy in adults. Annu Rev Med 2003; 54: 513-33.
10. Doward L, Mckenna S. The development of the AGHDA: a measure to assess quality of life of adults with growth hormone deficiency. Quality of Life Res 1995; 4: 420.
11. Gilchrist FJ, Murray RD, Shalet SM. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults. Clin Endocrinol (Oxf) 2002; 57: 363-70.
12. Hoffman AR, Strasburger CJ, Zagar A, Blum WF, Kehely A, Hartman ML on behalf of the T002 Study Group. Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison to fixed body weight-based dosing. J Clin Endocrinol Metab 2004 (in press).
13. M) - a short questionnaire for assessing subjective quality of life. Eur J Psychol Assess 2000; 16: 150-9.
14. Herschbach P, Henrich G, Strasburger CJ et al. Development and psychometric properties of a disease-specific quality of life questionnaire for adult patients with growth hormone deficiency. Eur J Endocrinol 2001; 145: 255-65.
15. Huber D, Henrich G, Herschbach P. Measuring the quality of life: a comparison between physically and mentally chronically ill patients and healthy persons. Pharmacopsychiatry 1988; 21: 453-55.
16. Hunt SM, Mcewan J, Mckenna SP. Measuring health status. London: Croom Helm, 1986.
17. Leplege A, Ecosse E, Archambeau F et al. Étude pilote et validation préliminaire de la version française d'un questionnaire de mesure de la qualité de vie spécifique des sujets atteints de déficit en hormone de croissance. Ann Endocrinol 2003; 64: 191-7.
18. Mcgauley GA. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Paediatr Scand 1989; Suppl 356: 70-2.
19. Mckenna SP, Doward LC, Alonso J et al. The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 1999; 8: 373-83.
20. Murray RD, Skillicorn CJ, Howell SJ et al. Influences on quality of life in GH deficient adults and their effect on response to treatment. Clin Endocrinol (Oxf) 1999; 51: 565-73.
21. Norusis MJ. SPSS Base System User's guide. SPSS Inc., Chicago, 1990.
22. Prieto L, Roset M, Badia X. Rasch measurement in the assessment of growth hormone deficiency in adult patients. J Appl Meas 2001; 2: 48-64.
23. Rosilio M, Blum WF, Edwards DJ et al. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency as measured by QLS-H. J Clin Endocrinol Metab 2004; 89: 1684-93.
24. Schlienger JL, Goichot B. Hormone de croissance: potion magique? Rev Med Interne 1998; 19: 279-85.
25. Simpson H, Savine R, Sönksen P et al. Growth hormone replacement therapy for adults: into the new millennium. Growth Hormone & IGF Research 2002; 121: 1-33.
26. Wallymahmed ME, Foy P, Shaw D et al. Quality of life, body composition and muscle strength in adult growth hormone deficiency: the influence of growth hormone deficiency: the influence of growth hormone replacement for up to 3 years. Clin Endocrinol (Oxf) 1997; 47: 439-46.
27. Ware JE, Sherbourne CD. The MOS 36-item short form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
28. Wiren L, Johansson G, Bengtsson BA. A prospective investigation of quality of life and psychological well-being after the discontinuation of GH treatment in adolescent patients who had GH deficiency during childhood. J Clin Endocrinol Metab 2001; 86: 3494-8.
29. Wiren L, Whalley D, Mckenna S, Wilhelmsen L. Application of a disease-specific, quality of life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: validation of the measure by Rasch analysis. Clin Endocrinol (Oxf) 2000; 52: 143-52.